Raj Asarpota serves as the Chief Financial Officer of Maravai LifeSciences Holdings, Inc., a leading provider of life sciences reagents and services critical for nucleic acid production and drug development. With over two decades of experience in finance and accounting within the healthcare and life sciences sectors, Asarpota joined Maravai in September 2021, bringing expertise in financial strategy, mergers and acquisitions, and capital markets. He holds an MBA from UCLA Anderson School of Management and a Bachelor of Science in Accounting from the University of Southern California, which laid the foundation for his distinguished career. Prior to Maravai, Asarpota was CFO at Axonics Modulation Technologies, Inc., from 2018 to 2021, where he played a pivotal role in the company's successful initial public offering on the Nasdaq in 2018, raising over $165 million and enabling rapid growth in neuromodulation therapies. Before that, he held progressive finance leadership roles at St. Jude Medical, including Director of Finance for the Cardiac Rhythm Management International division from 2015 to 2018, overseeing financial operations across Europe, the Middle East, Africa, and Canada. Earlier in his career, Asarpota spent nearly a decade at Deloitte & Touche LLP as an Audit Senior Manager, specializing in healthcare clients and honing his skills in complex financial reporting and compliance. At Maravai, Asarpota leads all financial functions, including accounting, treasury, tax, investor relations, and risk management, supporting the company's expansion in high-growth areas like mRNA and oligonucleotide manufacturing. His strategic oversight has been instrumental in navigating post-pandemic market dynamics, driving operational efficiencies, and positioning Maravai for sustained profitability and innovation in the biotech supply chain.